论文部分内容阅读
已知选择性α受体阻断剂是通过作用于BPH尿动力环节来消除BPH症状和改善尿动力学参数。Akan H等进行的研究采用IPSS评分和尿动力学参数检查评价多沙唑嗪治疗BPH的疗效。入选24例患者服用多沙唑嗪4 mg／d,19例患者服用安慰剂。在3周用药期内进行IPSS评分和尿动力学参数检测。3周后,多沙唑嗪组IPSS评分显著低于安慰剂组(47％/12％,P<0．05),但尿动力学参数两组间无明显改善(最大尿流率24％,16％,P>0．05)。6周后,与安慰剂组相比,多沙唑嗪组IPSS评分继续改观,并且尿动力学
Selective α-blockers are known to counteract BPH symptoms and improve urodynamic parameters by acting on the BPH urodynamics. Akan H and other studies conducted using IPSS score and urodynamic parameters to evaluate the efficacy of doxazosin treatment of BPH. Twenty-four patients received doxazosin 4 mg daily, and 19 patients took placebo. IPSS scores and urodynamic parameters were tested during the 3-week dosing period. After 3 weeks, the IPSS score of doxazosin group was significantly lower than that of placebo group (47% / 12%, P <0.05), but there was no significant difference in urodynamic parameters between the two groups (maximal uroflow rate was 24% 16%, P> 0.05). After 6 weeks, the IPSS scores continued to improve in the doxazosin group compared with placebo, and urodynamic